News

The agreement grants UCB non-exclusive rights to research and develop antibodies for an undisclosed number of targets. In return, BioWa will receive license fees, milestone payments and royalties

Regeneron said its VelocImmune technology offers the potential to increase dramatically the speed and efficiency of discovering fully-human, therapeutic monoclonal antibodies. The VelocImmune mouse, unlike other human monoclonal

The agreement includes an upfront payment, milestones and research funding potentially totaling up to $110 million over the life of the agreement. Wyeth will also pay Elbion royalties

The filing in Japan is a result of a development collaboration between ImClone Systems, Bristol-Myers Squibb, and Merck KGaA. Merck licensed the drug from ImClone Systems. The Japanese

Wyeth said these extended half-life proteins will be designed to enhance patient convenience as they will reduce the number and frequency of treatments needed. As part of the

The drug, ACT-078573, is the first oral orexin receptor antagonist that penetrates the blood-brain barrier and is capable of inducing a transient and reversible blockade of the two

The study is the first randomized, double blind, placebo-controlled trial to evaluate a biologic agent in the treatment of this uniquely challenged subpopulation of psoriasis patients. The primary

Investigators reported that that patients with moderate to severe plaque psoriasis receiving Remicade induction and maintenance therapy experienced significant improvements in productivity at week 10, which were sustained

Ranbaxy won US approval for a generic version of Valtrex at the beginning of this month, but GSK originally filed a lawsuit regarding Valtrex patents in 2003. GSK